Episode 3: The Pathologist-Oncologist Connection - Optimal Reporting of the PD-L1 Results

In this third episode of the "Dialogues in CDx" podcast series, you’ll listen to the distinguished guests Dr. Phillippe Taniere and Dr. Shobhit Baijal once more. The previous episode dissected the PD-L1 testing journey from biopsy to report. This episode will focus on the topic of PD-L1 reporting: What information should the pathologist provide for the oncologist? What information helps the oncologist make the best treatment decisions?

As in the second episode, perspectives from both a pathologist and an oncologist are presented. Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham in UK. Dr. Taniere’s department completed 20,000 CDx tests last year.

Also joining the discussion is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham, where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion.

This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.

For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's ⁠CDx Digital Education Portal⁠ today.

D0130749_1.00